{"id":37,"date":"2021-10-01T12:18:50","date_gmt":"2021-10-01T10:18:50","guid":{"rendered":"http:\/\/www.congressi.unisi.it\/ebvconferencesiena\/?page_id=37"},"modified":"2022-06-22T11:43:07","modified_gmt":"2022-06-22T09:43:07","slug":"preliminary-scientific-program","status":"publish","type":"page","link":"https:\/\/www.congressi.unisi.it\/ebvconferencesiena\/preliminary-scientific-program\/","title":{"rendered":"Scientific program"},"content":{"rendered":"\n

Sunday July 3<\/span><\/strong>
18.30 \u2013 21.00<\/strong> 
Registration
Welcome Reception with \u201cApericena\u201d
(Presidio Mattioli, Via Mattioli 10)

Monday July 4<\/span><\/strong>
MORNING SESSION
8.30-9.00 <\/strong>Welcome remarks: Lorenzo Leoncini and Pankaj Trivedi<\/strong>

09.00-11.00 EBV infection and viral replication<\/strong>
Chair: Michelle West and Paul Farrell
<\/strong>
9.00 Topic Lecture
Erle Robertson<\/strong>, Department of Otorhinolaryngology-Head and Neck Surgery, and the Tumor Virology Program, University of Pennsylvania, USA<\/em>
M6A modification of the host epitranscriptome attenuates IFN signaling and Promotes EBV lytic reactivation<\/strong>

<\/em>09.20 Michael T. McIntosh<\/a><\/strong> (USA<\/em>). EBV LMP-1 forms a K+<\/sup> selective oncochannel that supports LYTIC virus release

09.35 Francesco Baccianti<\/strong> <\/a>(Germany<\/em>). Epstein-Barr virus infection of resting B cells requires activation of multiple signaling pathways that converge onto the stress protein ZFP36L1

9.50 Sumita Bhaduri-McIntosh<\/a><\/strong> (USA<\/em>). EA-d directs traffic at the intersection of EBV transcription and replication

10.05 Ana Catalina Blazquez<\/strong><\/a> <\/strong>(Argentina<\/em>). Could Epstein Barr virus type 2 asymmetric circulation be explained with an Immunoinformatic approach?<\/p>\n\n\n\n

10.20 Sankar Swaminathan<\/a><\/strong><\/strong> (USA<\/em>). Effects of RAD21 and CTCF on EBV reactivation from latency

10.35 Davide Maestri<\/a><\/strong> (USA<\/em>, Italy<\/em>). Epstein-Barr Virus rewires host genome through CTCF and PARP1 relocation
<\/p>\n\n\n\n

11.00 \u2013 11.20 Coffee break and Poster viewing<\/p>\n\n\n\n

11.20-13.00 EBV latency program and reactivation<\/strong>
Chair: Pankaj Trivedi<\/strong> and Alberto Faggioni<\/strong>

<\/strong>11.20 Topic Lecture
Paul Liebermann<\/strong>, Gene Expression & Regulation Program, The Wistar Institute, USA<\/em>
Control of EBV Latency by EBNA1 in Cancer and Multiple Sclerosis<\/strong><\/p>\n\n\n\n

11.40 <\/strong>Ezgi Akidil<\/strong> <\/a>(Germany<\/em>). Histone Chaperone CAF1 is essential for the survival of EBV-infected primary B cells and the establishment of viral latency<\/p>\n\n\n\n

11.55\u00a0<\/em>Katherine A. Willard<\/a><\/strong> <\/strong>(USA<\/em>).<\/strong>\u00a0Novel Epstein Barr virus strains isolated from endemic Burkitt lymphoma patients display unusual and reversible spontaneous lytic phenotypes<\/p>\n\n\n\n

12.10 Bill Sugden<\/a><\/strong> (USA<\/em>). Epstein-Barr virus manipulates cellular chromatin structure during its lytic phase<\/p>\n\n\n\n

12.25 Jillian A. Bristol<\/a><\/strong><\/strong> (USA<\/em>). Reduced IRF4 level contributes to lytic phenotype of type 2 EBV infected B cells<\/p>\n\n\n\n

12.40 Italo Tempera<\/a><\/strong> (USA<\/em>). PARP1 and CTCF interaction guides EBV chromatin refolding to promote viral gene expression and sustain cell proliferation during latency<\/p>\n\n\n\n

13.00 – 14.30 Lunch and poster viewing<\/p>\n\n\n\n

AFTERNOON SESSION

14.30-16.00 Mechanism of EBV oncogenesis<\/strong>
Chairs: Sankar Swaminathan and Gian Maria<\/strong> Rossolini<\/strong>

<\/strong>14.30 Topic Lecture
Bill Sugden<\/strong>, WI Institutes for Medical Research, Universit\u00e0 del Wisconsin-Madisom, <\/em>USA
What Epstein-Barr virus contributes to B cell lymphoma<\/strong>.<\/p>\n\n\n\n

14.50 <\/a>Alejandro Casco<\/a><\/strong> <\/strong>(USA<\/em>). <\/strong>What can a fluorescent Epstein-Barr virus tell us about host-shutoff?<\/p>\n\n\n\n

15.05 Elliott D. SoRelle<\/a><\/strong> (USA<\/em>). Time-resolved multiomics reveal distinct B cell fates and gene regulatory signatures in the early stages of Epstein-Barr Virus infection<\/p>\n\n\n\n

15.20 Noemi Nagy<\/a><\/strong> (Sweden<\/em>).The Epstein-Barr virus deubiquitinating enzyme BPLF1 supports cell survival and virus production by regulating the activity of topoisomerase II<\/p>\n\n\n\n

15.35 <\/em>Sheldon Steyn<\/a><\/strong> (Germany<\/em>). Oncogenic properties of the Epstein Barr Virus Large Tegument Protein<\/p>\n\n\n\n

15.50 Francesca Manara<\/a><\/strong> (France<\/em>). Key epigenetic events during EBV-mediated B cell transformation<\/p>\n\n\n\n

16.10 \u2013 16.30 Coffee break and Poster Viewing<\/p>\n\n\n\n

16.30-18.00 EBV Associated Epithelial Cancers<\/strong><\/strong>
Chairs: Bill Sugden<\/strong> and<\/strong> Anita De Rossi<\/strong>

<\/strong>16.30 Topic Lecture
Hironori Yoshyama<\/strong>, Department of Microbiology, Shimane University, Izumo, Shimane, Japan
Epithelial cell tumors<\/strong><\/p>\n\n\n\n

16.50 Shannon C. Kenney<\/strong> <\/a>(USA<\/em>). LMP1 promotes proliferation, and inhibits differentiation, in EBV-infected telomerase-immortalized normal oral keratinocytes (NKs) by activating the hippo pathway effectors, YAP and TAZ<\/p>\n\n\n\n

17.05 <\/em>Salvatore Tornamb\u00e8<\/a><\/strong> (Italy<\/em>). EBV persistence in gastric cancer cases conventionally classified as EBER-ISH negative<\/p>\n\n\n\n

17.20 Ciara Leahy<\/strong><\/a> (Ireland<\/em>). Exploring gene and protein expression in the tumour and tumour microenvironment of nasopharyngeal carcinoma<\/p>\n\n\n\n

17.35 Atsushi Kaneda<\/a><\/strong> (Japan<\/em>). Epstein-Barr virus infection rewires host chromatin structure and epigenetically contributes to tumorigenesis in tissue wide manner<\/p>\n\n\n\n

17.50 Joanna B. Wilson<\/strong> <\/a>(UK<\/em>). Mouse models of EBV associated disease, from understanding mechanism to pre-clinical model<\/p>\n\n\n\n

Tuesday July 5<\/span><\/strong>
MORNING SESSION
<\/strong>
09.00-11.00 EBV Associated Lymphomas- Session 1: Diffuse Large B Cell Lymphoma and Burkitt Lymphoma<\/strong><\/strong><\/strong>
Chairs: Cesarman Ethel and Stefan Dojcinov<\/strong>

<\/strong>09.00 Topic Lecture I
Ioannis Anagnostopoulos<\/strong>, <\/strong>Institut f\u00fcr Pathologie, Universit\u00e4t W\u00fcrzburg, Germany<\/em>
EBV- positive diffuse large B-cell lymphoma<\/strong><\/p>\n\n\n\n

09.20 Topic Lecture II
Rosemary Rochford<\/strong>, Department of Immunology and Microbiology, University of Colorado, <\/em>USA
Uncovering the etiology of Burkitt lymphoma<\/strong><\/p>\n\n\n\n

9.40 Tamara Soledad Mangiaterra<\/strong><\/strong><\/a> (Argentina<\/em>). Detection of EBV antigens by unconventional methods in DLBCL from Argentina diagnosed as EBV negative<\/p>\n\n\n\n

9.55 Rebecca L Hutcheson<\/a> <\/strong>(USA<\/em>). <\/strong>Sequential CRISPR knockout screening reveals cellular genes compensating for Epstein-Barr Virus in Burkitt Lymphoma cell lines<\/p>\n\n\n\n

10.10 <\/em>Amy Chadburn<\/a><\/strong> (USA<\/em>). Revisiting EBV expression patterns in lymphoma<\/p>\n\n\n\n

10.25 Jez L. Marston<\/a><\/strong> (USA<\/em>). EBV latency III program induces expression of HERVK(HML2) loci in Burkitt Lymphoma cell lines<\/p>\n\n\n\n

10.40 Cliff I. Oduor<\/strong> <\/a>(USA<\/em>). Patient-derived endemic Burkitt Lymphoma avatar mouse models for exploring inter-patient tumor variation and testing targeted therapies<\/p>\n\n\n\n

11.00 \u2013 11.20 Coffee break and Poster viewing

11.20-13.00 EBV Associated Lymphomas: Session 2<\/strong><\/strong>
Chairs: Amy Chadburn and Antonino Carbone<\/strong>

11.20 Topic Lecture
Leticia Quintanilla Fend<\/strong>, <\/strong><\/strong>Department of Pathology, University of Tubingen, <\/em>Germany
Challenges in EBV+ T and NK cell lymphoproliferations<\/strong><\/p>\n\n\n\n

11.45 Aisling Ross<\/a><\/strong> (Ireland, UK<\/em>). Investigating Lymphomagenesis using Transformed Germinal Centre B Cells as a Model of EBV+<\/sup> Diffuse Large B cell Lymphoma<\/p>\n\n\n\n

12.00 Gabriela<\/a><\/strong> <\/a><\/em>Samayoa-Reyes<\/a><\/strong> (USA<\/em>). Effect of age and malaria infection on Epstein – Barr viral reactivation in children<\/p>\n\n\n\n

12.15 Paul J. Farrell<\/a><\/strong> (UK<\/em>).Epstein-Barr Virus genome deletions in EBV+ T\/NK cell lymphoproliferative diseases<\/p>\n\n\n\n

12.30 Nader Bayda<\/a><\/strong> (France<\/em>). Analysis of Epstein-Barr virus transcriptome in angioimmunoblastic T cell lymphoma (AITL) comparatively to other human lymphomas<\/p>\n\n\n\n

12.45 Ioannis<\/strong> Anagnostopoulos<\/strong><\/a> (Germany<\/em>). Epstein-Barr-Virus infectionpatterns in nodular lymphocytepredominant Hodgkin-lymphoma<\/p>\n\n\n\n

13.00 – 14.30 Lunch and poster viewing

AFTERNOON SESSION<\/p>\n\n\n\n

14.30-16.00 EBV and tumor microenvironment<\/strong><\/strong>
Chairs: Ann Moormann<\/strong> and<\/strong> Falko Fend<\/strong><\/strong>

<\/strong>14.30 Topic Lecture
Christian M\u00fcnz,<\/strong> Viral Immunobiology, Institute of Experimental Immunology, University of Zurich, <\/em>Switzerland
The microenvironment of EBV specific immune control<\/strong><\/p>\n\n\n\n

14.50 \u00c9anna Fennell<\/strong><\/a> <\/strong>(Ireland<\/em>). Highly multiplexed, single-cell spatial phenotyping of Epstein-Barr virus associated lymphomas<\/p>\n\n\n\n

15.05 Ann M. Moormann<\/a><\/strong> (USA<\/em>). Single cell landscape of tumor infiltrating T cells in endemic Burkitt lymphoma Patients<\/p>\n\n\n\n

15.20 <\/strong>Agustina<\/strong> Moyano<\/strong><\/a> (Argentina<\/em>). Epstein Barr Virus\u00b4 role in the interplay of tonsil macrophages polarization and periphery cytokine expression<\/p>\n\n\n\n

15.35 Jennifer<\/strong> Saliba<\/strong><\/a> (France<\/em>). Role of fucoidans in the restoration of the anti-tumor T-cell response inhibited by EBV latency III B cells via<\/em> the PD-L1 immune checkpoint<\/p>\n\n\n\n

15.50 Maria Chiara Siciliano<\/a><\/strong> (Italy). <\/em>Epstein-Barr virus orchestrate the Tumor Microenvironment of Burkitt Lymphoma<\/p>\n\n\n\n

16.10 \u2013 16.30 Coffee break and poster viewing

16.30-17.30 Henle Lecture 2022<\/strong>
Shannon Kenney<\/strong> “EBV regulation in B cells versus epithelial cells\u201d

17.30-18.00 General assembly:  EBV association members<\/strong><\/p>\n\n\n\n

20.30 Social Dinner<\/p>\n\n\n\n

Wednesday July 6<\/span><\/strong>
MORNING SESSION

Chairs: Eleni Anastasiadou and Lori Frappier<\/strong>
09.00-11.00 EBV non-coding RNA regulation and other trasforming mechanisms<\/strong>

9.00 Topic Lecture
Lori Frappier<\/strong>, Department of Molecular Genetics, University of Toronto, Toronto, Canada
Analysis of Changes in the SUMO Proteome In Response To EBV Lytic Infection Identifies the TRIM24\/28\/33 Complex as an EBV Regulator<\/strong>

9.20 Ashley M Campbell<\/a><\/strong> (Canada<\/em>). BGLF2 interferes with cellular miRNA function by binding RISC<\/p>\n\n\n\n

9.35 <\/a>Jiayan LIU<\/a> <\/strong>(China<\/em>). <\/a>Role of Epstein-Barr Virus lnc-BARTs<\/em>\/BRD4 Axis in Promoting Nasopharyngeal Carcinoma<\/p>\n\n\n\n

9.50 Suk Kyeong Lee<\/a><\/strong> (Korea<\/em>). Epstein-Barr Virus miR-BART1-3p Regulates the miR-17-92 Cluster by Targeting E2F3<\/p>\n\n\n\n

10.05 Rena R. Xian<\/strong><\/a> (USA<\/em>). Can EBV CPG methylation in plasma distinguish EBV lymphoma (+) subtypes?<\/p>\n\n\n\n

10.20 Eleni Anastasiadou<\/a><\/strong> (Italy<\/em>). Epstein-Barr virus: from kisses to cancer, an ingenious immune evader<\/p>\n\n\n\n

10.35 Eric C.Johannsen <\/strong><\/a>(USA<\/em>). An EBV mutant deleted for the IE locus reveals Rta to be the dominant early gene activator and Zta acts primarily at OriLyt

11.00 Coffee break and poster viewing

11.20 – 13.00 EBV and Multiple Sclerosis
Chairs: Christian M\u00fcnz and Jaap Middeldorp<\/strong><\/p>\n\n\n\n

11.20-13.00 EBV and Multiple Sclerosis<\/strong><\/p>\n\n\n\n

11.20 Topic Lecture
Ascherio Alberto,<\/strong> Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, <\/em>USA
EBV as the leading cause of multiple sclerosis<\/strong><\/p>\n\n\n\n

11.40 Marc S. Horwitz<\/a><\/strong> (Canada<\/em>). Epstein-Barr virus infection promotes Th1-mediated disease in a humanized immune mouse model of multiple sclerosis<\/p>\n\n\n\n

11.55 John B. Harley<\/a><\/strong> (USA<\/em>). Proline-rich EBNA1 epitopes initiate cross-reacting autoantibodies in Systemic Lupus Erythematosus (SLE) & Multiple Sclerosis (MS)<\/p>\n\n\n\n

12.10 Caterina Veroni<\/a><\/strong> (Italy<\/em>). Detection of EBV nucleic acids in brain immune infiltrates, cerebrospinal fluid and peripheral blood of patients with multiple sclerosis<\/p>\n\n\n\n

12.30 \u2013 14.00 Poster session and Lunch

AFTERNOON SESSION<\/p>\n\n\n\n

14.00-16.30 Diagnostics, Vaccines, and Therapy <\/strong>
Chairs: Richard Ambinder and Gianni Pozzi<\/strong><\/p>\n\n\n\n

14.00 Topic Lecture
Jeffery Cohen<\/strong>, National Institute of Allergy and Infectious Diseases, National Institutes of Health, <\/em>USA
Strategies to prevent EBV-associated diseases<\/strong><\/p>\n\n\n\n

14.20 Michelle J. West<\/a> <\/strong>(UK<\/em>). Natural variants of EBNA1 differ in their DNA binding and replication properties and sensitivity to inhibitors<\/p>\n\n\n\n

14.35 Wei Bu<\/a><\/strong> (USA<\/em>). A Potent GP42 Monoclonal Antibody Neutralizes EBV Infection and Protects Humanized Mice from EBV Infection<\/p>\n\n\n\n

14.50 Silvia Giunco<\/strong><\/a> (Italy<\/em>). Anti-proliferative effects of combined treatment with TERT inhibitor and chemotherapeutic agents in EBV-positive malignant B cells xenografted in zebrafish<\/p>\n\n\n\n

15.05 Arnd Kieser<\/a><\/strong> (Germany<\/em>). Highly Efficient small molecule inhibitors of LMP1-TRAF2 interaction block LMP1 signaling and interfere with LCL and PTLD Survival<\/p>\n\n\n\n

15.20 Harman Malhi<\/a><\/strong> (USA<\/em>). Immunization with a self-assembling nanoparticle vaccine displaying EBV gH\/gL protects humanized mice against lethal viral challenge<\/p>\n\n\n\n

15.35 Ayman Elguindy<\/a><\/strong> (USA<\/em>). Targeting Epstein-Barr virus-associated malignancies using \u201cKick and Kill\u201d<\/p>\n\n\n\n

15.50 Maher K Gandhi<\/strong> <\/a>(Australia<\/em>). The tumour microenvironment and genetic profile of EBV+ primary CNS lymphomas in amenable to combination 3rd party EBV-specific VST, Ibrutinib and Rituximab.<\/p>\n\n\n\n

16.05 Vijayendra Dasari<\/a><\/strong> (Australia<\/em>). A lymph node targeted molecular adjuvant and engineered subunit antigen vaccine promotes potent cellular and humoral immunity to Epstein-Barr virus in HLA-expressing mice<\/p>\n\n\n\n

16.20 Closing remarks<\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Sunday July 318.30 \u2013 21.00  Registration Welcome Reception with \u201cApericena\u201d (Presidio Mattioli, Via Mattioli 10)Monday July 4MORNING SESSION8.30-9.00 Welcome remarks: Lorenzo Leoncini and Pankaj Trivedi09.00-11.00 EBV infection and viral replicationChair: Michelle West and Paul Farrell9.00 Topic LectureErle Robertson, Department of Otorhinolaryngology-Head and Neck Surgery, and the Tumor Virology Program, University of Pennsylvania, USAM6A modification of … Leggi tutto<\/a><\/p>\n","protected":false},"author":5,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"saved_in_kubio":false,"footnotes":""},"class_list":["post-37","page","type-page","status-publish"],"kubio_ai_page_context":{"short_desc":"","purpose":"general"},"_links":{"self":[{"href":"https:\/\/www.congressi.unisi.it\/ebvconferencesiena\/wp-json\/wp\/v2\/pages\/37","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.congressi.unisi.it\/ebvconferencesiena\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.congressi.unisi.it\/ebvconferencesiena\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.congressi.unisi.it\/ebvconferencesiena\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.congressi.unisi.it\/ebvconferencesiena\/wp-json\/wp\/v2\/comments?post=37"}],"version-history":[{"count":104,"href":"https:\/\/www.congressi.unisi.it\/ebvconferencesiena\/wp-json\/wp\/v2\/pages\/37\/revisions"}],"predecessor-version":[{"id":485,"href":"https:\/\/www.congressi.unisi.it\/ebvconferencesiena\/wp-json\/wp\/v2\/pages\/37\/revisions\/485"}],"wp:attachment":[{"href":"https:\/\/www.congressi.unisi.it\/ebvconferencesiena\/wp-json\/wp\/v2\/media?parent=37"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}